KIF1A-Associated Neurological Disorder · KAND

What this is

KIF1A-Associated Neurological Disorder (KAND) is caused by heterozygous mutations in KIF1A, the gene encoding a kinesin family motor protein essential for transporting cargo along axons. The mutations are typically de novo (occurring in the affected child but not in either parent) and dominant, meaning a single damaging copy is sufficient to produce disease. The mechanism is loss of effective motor protein function in long projection neurons; without intact axonal transport, neuronal maintenance fails progressively.

The clinical phenotype includes developmental delay apparent in infancy, progressive intellectual disability, spastic paraplegia, optic atrophy, microcephaly, epilepsy of varying types, and progressive motor regression. The course is steady deterioration through childhood and adolescence in most affected children. Severity varies by specific mutation; some variants produce predominantly ataxic forms, others produce earlier-onset and more aggressive disease.

Approximately 600 affected individuals worldwide have been identified, making KAND the largest of the kinesinopathies and one of the better-characterized ultra-rare pediatric neurological disorders. The condition was first molecularly characterized in 2011, and the patient-facing foundation, KIF1A.org, was incorporated by affected families in 2017. The KAND Natural History Study, run by Wendy Chung's lab (initially at Columbia, now at Boston Children's Hospital), is the field's reference dataset for clinical course, biomarkers, and outcome measures.

There is no approved disease-modifying therapy. Standard of care is anticonvulsant management for the seizures, supportive therapy for motor disability, vision support as the optic atrophy progresses, and educational accommodations. Almost all affected children require substantial daily care throughout life.

The case

Susannah Rosen was born in 2014 to Luke Rosen and Sally Jackson in New York. By her second year, her parents and pediatricians had noticed delayed milestones. Diagnostic workup at Columbia University Irving Medical Center, including genetic testing under the care of Wendy Chung, identified a heterozygous missense variant in KIF1A in August 2016, when Susannah was two years old. The variant has been reported in a total of approximately eight people worldwide.

The diagnosis named the disease and produced no treatment, no clinical trial, and no path to one. Chung advised the family that the most useful thing they could do was identify the broader population of KAND patients, both to support the affected families and to make eventual research feasible. Luke Rosen and Sally Jackson incorporated KIF1A.org in 2017 to do exactly that. The foundation has since identified more than 400 affected children and adults globally and raised approximately two million dollars in research funding through community fundraising and individual donations.

Susannah's clinical trajectory through her early childhood and into elementary school was the typical KAND course of progressive deterioration. By age nine, she was experiencing 100 to 290 seizures per day, falling on average 26.2 times per day, and had sustained multiple bone fractures from the falls. Her speech was limited to short sentences with long pauses. Her motor function was deteriorating despite the family's substantial therapy and care infrastructure.

In approximately mid-2021, the n-Lorem Foundation accepted Susannah's case into its individualized antisense oligonucleotide pipeline. The molecular target of the drug was Susannah's specific missense variant: an allele-selective ASO designed to suppress translation of the mutant KIF1A allele while preserving expression of her wild-type allele. The seventeen months from acceptance to first dose included candidate ASO design and screening, in vitro validation in patient-derived cells, manufacturing under good manufacturing practices, regulatory submission to the FDA under an emergency or sponsor-investigator IND, and dose-preparation work.

Susannah received her first intrathecal dose in October 2022 at Columbia, with the program led by Wendy Chung. She was eight years old.

The clinical changes after dosing were rapid. Within the first month, her gait improved, her falls dropped to a maximum of seven per day with many days having no falls at all, her seizure frequency declined, and her caregivers and clinicians reported improvements in her speech quality, attention, engagement in activities, and ability to participate in group settings. Her cognitive baseline remained stable, which is an important distinction in a progressive disease where the alternative is continued decline.

As of August 2024, Susannah had been on the ASO treatment for approximately twenty months. The safety profile was favorable, with no ASO-related serious adverse events. The clinical observations were published in Nature Medicine in August 2024 as a peer-reviewed account of the n-Lorem-treated KAND case.

The research

The molecular design of Susannah's drug was unusual in the n-Lorem catalog because it required allele selectivity. KIF1A is a dominant-acting gene with a single damaging copy producing disease through a gain-of-function or dominant-negative mechanism. Suppressing both alleles would not just reduce the toxic mutant protein; it would also reduce the wild-type protein the cell still needs. The ASO Susannah received is therefore designed to bind a sequence in the mutant transcript that distinguishes it from the wild-type, allowing selective knockdown.

The chemistry is the standard 2'-O-methoxyethyl phosphorothioate gapmer that the field uses, with the sequence-specific allele selectivity achieved through careful design around the missense variant site. The mechanism of action is RNase H-mediated cleavage of the targeted mutant transcript. The intrathecal delivery route is the same as nusinersen, milasen, atipeksen, valeriasen, and the broader n-Lorem catalog.

The data infrastructure that made the program possible is the KAND Natural History Study Chung's lab has been building since the foundation's incorporation in 2017. The registry provided baseline measures of seizure frequency, fall rate, motor function, speech, and other clinical endpoints from approximately 400 KAND-affected individuals worldwide, against which Susannah's trajectory could be compared. Without that natural-history data, the apparent improvements in Susannah's clinical course after dosing would have been harder to interpret with confidence; against the registry, the difference between her pre-treatment trajectory and her post-treatment trajectory is measurable.

Funding for the program came primarily from n-Lorem (which covers the development and manufacturing costs for accepted nano-rare patients through philanthropic donations) with research and clinical support from KIF1A.org, the Chung Lab, and the broader Columbia and Boston Children's institutional infrastructure.

What is blocking the next case

The next case in KAND is structurally different from Susannah's. Her mutation is shared by approximately eight identified individuals globally, so the same ASO that worked for her could in principle work for the others, if their conditions are similar enough and their disease has not progressed too far. n-Lorem's pipeline includes evaluation of additional KAND families with the same variant, and the Foundation is in the process of screening them for eligibility.

Other KAND families have different KIF1A variants, each of which would in principle require its own allele-selective ASO design. The total population of affected individuals is roughly 600, but the variant heterogeneity means that a given allele-specific ASO addresses a subset of the population. n-Lorem's working assumption is that several variants are common enough across the cohort to support drug development for shared variants, while singletons would each require their own program.

The throughput constraint is the same one the field as a whole faces: small-batch GMP manufacturing capacity, regulatory bandwidth for a growing pipeline of similar but not identical sponsor-investigator INDs, and the philanthropic funding that subsidizes the per-program cost. Each KAND program n-Lorem accepts increases the cumulative safety database for the chemistry class and the route, which makes subsequent programs faster, but the absolute number of programs the Foundation can run per year is bounded.

The other open question is whether the magnitude of Susannah's clinical response will hold over years of continued dosing, and whether earlier intervention in younger children with the same variant produces correspondingly better outcomes. The answers will come from the second, third, and tenth treated individual, not from any single case.

Where this connects

The natural-history infrastructure that makes the KAND program scientifically interpretable is described in Wendy Chung and the natural-history-first model. The institutional model that funded and developed Susannah's drug is described in Stanley Crooke and the n-of-many foundation. The chemistry that made the allele-selective ASO design possible is described in How splice-switching ASOs work, although Susannah's drug uses gapmer chemistry and the RNase H mechanism rather than splice modulation.

Sources

• KIF1A.org. Foundation history, registry partnership with Chung Lab. https://www.kif1a.org
• n-Lorem Foundation. Press release: positive clinical observations from n-Lorem-treated KIF1A nano-rare patient published in Nature Medicine. August 2024.
• Boyle EA, Wong M, Chung WK. KIF1A-related disorder. In: GeneReviews. Updated entry on KAND.
• Charles River Laboratories Eureka blog. The journey of Susannah's personalized ASO. 2024.
• Columbia University Irving Medical Center. Columbia doctors use customized drug to treat patient with very rare disease. 2024.
• Oligonucleotide Therapeutics Society. Personalized ASO provides improvements for a girl with KAND, an ultra-rare disease. 2024.
• CNBC. This 11-year-old has battled a rare disease for years; a breakthrough drug helped deliver relief. January 2026.
• Klebe S, Lossos A, Azzedine H, et al. KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations. Eur J Hum Genet. 2012;20(6):645-649. (Earlier characterization of the KIF1A clinical and genetic spectrum.)